Please assess the completion status of the following clinical trial:

Trial Title: Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known sarcoidosis 21.~* Age 18 or greater~* Patients with documented pulmonary hypertension with a PA mean \> 25 mm Hg as measured by cardiac catheterization within six months of entry into the study. Pulmonary artery occluding pressure and or left ventricular end diastolic pressure must be less than 15 mm Hg.~* Patients with WHO class II or III~* Six minute walk distance of between 100 to 500 meters~* Patients on stable immunotherapy for their sarcoidosis, including prednisone, methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or infliximab~* Patients able to provide written consent~Exclusion Criteria:~* Patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) n the prior 28 days. Patients on stable dose of calcium channel blocker for more than 1 month prior to right heart catheterization can be continued on the calcium channel blocker.~* Patients with severe airway obstruction as defined by FEV1/FVC of less than 35%~* Patients with World Health Organization (WHO) class IV status.~* Patients who are pregnant or breast feeding~* Patients with significant left ventricular dysfunction with a left ventricular ejection fraction of less than 35%~* Cardiac index \< 2.0 liters and/or right atrial pressure \>15 mm Hg~* Significant liver dysfunction not due to sarcoidosis.~* Patients with severe other organ disease felt by investigators to impact on survival during the course of the study.~* Patients unable to perform the 6 minute walk study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bosentan for 16 weeks (Type: ACTIVE_COMPARATOR): Active drug
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).